UNSPSC 51183608: Insulin beef

This classification denotes a peptide hormone with the molecular formula C254H377N65O75S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 576O9IZ534, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG. The term INSULIN is an International Non-Proprietary Name.

INSULIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, INSULIN BEEF remains US FDA's Preferred Term for this commodity.

UNSPSC 51183608 Insulin beef, a Commodity code, maps to state and local procurement of generic pharmaceuticals and over-the-counter products supplied through cooperative purchasing alliances and distributed to government facilities, though the recent solicitation activity under this code does not isolate insulin beef as a distinct line item. State and local governments procure pharmaceuticals through multistate cooperative agreements administered by state procurement offices, with vendors supplying products to authorized wholesalers and then to participating facilities. The issuing bodies are state agencies acting as cooperative-purchasing administrators on behalf of multiple member jurisdictions, including other states and local government entities. Work involves pharmaceutical manufacturers or authorized distributors submitting detailed product specifications (including National Drug Codes, UPCs, strengths, dosage forms, and packaging configurations), certifying compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, and maintaining contractual relationships with designated wholesalers. Pricing is weighted heavily in evaluation (75 percent), with administrative fees, EDI capability, and format compliance accounting for the remainder.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP posted January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. The procurement covers participating state and local facilities in Minnesota and Oregon through three authorized wholesalers: AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Awarded contracts are effective July 1, 2026, with a two-year term and optional extensions. Vendors must carry commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and face performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding deadlines. The RFP indicates no specific set-asides or disadvantaged-enterprise restrictions in available documentation.